Vyome (NASDAQ:HIND) Issues Earnings Results

Vyome (NASDAQ:HIND) posted its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share for the quarter, Zacks reports. Vyome had a negative return on equity of 283.23% and a negative net margin of 270.58%.The company had revenue of $0.03 million for the quarter.

Vyome Stock Performance

HIND stock traded up $0.02 during midday trading on Thursday, hitting $1.94. 41,710 shares of the stock were exchanged, compared to its average volume of 587,978. The stock’s 50-day moving average price is $2.27 and its 200-day moving average price is $3.35. The stock has a market cap of $13.62 million, a price-to-earnings ratio of -0.02 and a beta of 1.38. Vyome has a fifty-two week low of $1.75 and a fifty-two week high of $33.16.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Weiss Ratings raised Vyome from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Litchfield Hills Research started coverage on Vyome in a report on Monday, May 4th. They issued a “buy” rating for the company. Finally, Zacks Research raised Vyome to a “hold” rating in a report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $15.00.

Hedge Funds Weigh In On Vyome

An institutional investor recently bought a new position in Vyome stock. Millennium Management LLC acquired a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned about 0.80% of Vyome as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.